NCT04750278View on ClinicalTrials.gov

A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 6, 2021

Primary Completion Date

April 18, 2022

Study Completion Date

April 18, 2022

Conditions
Severe to Critical COVID 19 With Associated ARDS
Interventions
DRUG

FP-025 100 mg

FP-025 100 mg BID

DRUG

FP-025 300 mg

FP-025 300 mg BID

DRUG

Placebo

Placebo BID

Trial Locations (8)

20850

Shady Grove Medical Center, Rockville

58701

Trinity Health Center, Minto

77030

Houston Methodist, Houston

United Medical Memorial Hospital, Houston

89102

University of Nevada, Las Vegas (UNLV) School of Medicine, Las Vegas

91911

Velocity Chula Vista, Chula Vista

91942

Velocity San Diego, La Mesa

97210

Legacy Health, Portland

Sponsors
All Listed Sponsors
lead

Foresee Pharmaceuticals Co., Ltd.

INDUSTRY

NCT04750278 - A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19 | Biotech Hunter | Biotech Hunter